Daily Roundup

VAS.ASX JAN.ASX SOL.ASX MDR.ASX BKW.ASX

Vanguard Announces Final Distributions for Australian ETFs

Vanguard Investments Australia Ltd has announced the final distribution amounts and distribution timetable for its range of Australian Exchange Traded Funds (ETFs). The distributions will be paid on 16 July 2025 to investors registered as security holders on the record date of 2 July 2025. The ex-distribution date is 1 July 2025. The announcement provides the final distribution amounts for 20 Vanguard ETFs, including the Vanguard Australian Shares Index ETF (VAS), Vanguard Australian Property Securities Index ETF (VAP), and Vanguard Australian Fixed Interest Index ETF (VAF). The Distribution Reinvestment Plan (DRP) is available for all the ETFs, and any DRP elections must be made by 5pm on the record date. Vanguard intends that the primary market for applications and redemptions and the secondary market trading of units will remain open during the distribution period. Investors are advised to ensure that the correct bank details have been provided to the registrar, Computershare, prior to the record date to ensure prompt distribution payments.

Janison Secures CA ANZ Contract Renewal and AI Deployment

Janison Education Group Limited has announced the renewal of its agreement with Chartered Accountants Australia and New Zealand (CA ANZ) for a further three-year term, valued at approximately $2 million. This extension reinforces a long-standing and trusted partnership, ensuring the continued delivery of high-stakes remote proctored assessments for the CA Program through to June 2028. In addition, CA ANZ has become the inaugural commercial customer for Janison's new AI-powered item development platform, Jai. This milestone represents a key validation of Janison's innovation roadmap, with Jai beginning to deliver on its promise of enhanced efficiencies in professional and education assessment development. The partnership aligns with both organizations' ambitions to embrace technology to improve quality, scalability, and learner outcomes.

Pricing of the $450m SOL Convertible Notes Repurchase

Washington H. Soul Pattinson and Company Limited ('Soul Patts') has successfully completed the reverse bookbuilding process to determine the quantum and the repurchase price of the outstanding $450 million Senior Unsecured Convertible Notes due 2030 ('Existing Notes'). Under the reverse bookbuilding process, approximately 97% of the outstanding $450 million Existing Notes will now be repurchased in two tranches. Approximately $218 million of the principal amount of the Existing Notes will be Repurchased for $271 million with a settlement date of 4 July 2025, and approximately $217 million of the principal amount of the existing Notes will be Repurchased for a price to be determined by reference to the closing price of Soul Patts ordinary shares one business day after shareholder approval at the SOL and BKW scheme vote with a settlement date 2 business days after that date. Following the Repurchase, it is expected that less than 15% in aggregate principal amount of the Existing Notes will be outstanding, such that Soul Patts may redeem all Existing Notes which remain outstanding following the Repurchase at their principal amount (plus accrued and unpaid interest to the relevant date fixed for redemption) in accordance with their terms and conditions.

MedAdvisor Sells ANZ Business to Jonas Software

MedAdvisor Limited has announced that it has entered into a binding share sale and purchase agreement (SPA) to sell the company's ANZ business division and associated intellectual property to Jonas Software AUS Pty Ltd (Jonas). Under the terms of the SPA, Jonas will acquire 100% of the fully diluted shares of MedAdvisor International Pty Ltd and its subsidiary Medicines Information Pty Ltd, as well as MedAdvisor's UK investment in Charac and all intellectual property used in connection with the target group's business, including the 'MedAdvisor' brand name. MedAdvisor's US business will continue to operate under a royalty-free license arrangement with Jonas. The headline price for the target group is $35M, plus an uncapped contingent consideration comprised of a three-year earn-out based on the performance of the target group in the three-year period after completion. MedAdvisor intends to use the proceeds from the sale to discharge its finance facilities with Partners For Growth, estimated to be approximately $23.5M, with the remaining funds to be deployed in conjunction with the company's ongoing strategic review of its US business operations.